A majority of the episodes of endophthalmitis caused by gram-negative bacteria are due to *Pseudomonas aeruginosa* and members of Enterobacteriaceae.\[[@ref1]\] *P. aeruginosa* endophthalmitis is typically a rapidly progressive, sight-threatening condition that demands immediate therapeutic intervention.\[[@ref2]\] The ability of *P. aeruginosa* to survive on minimal nutritional requirements and to tolerate a variety of physical conditions has allowed this organism to persist in both community and hospital settings.\[[@ref3]\]

The aim of this study was to compare the efficiency of standard dose intra-vitreal ceftazidime and different doses of intra-vitreal cefepime in the treatment of experimental *P. aeruginosa* endophthalmitis.

Materials and Methods {#sec1-1}
=====================

All the animal-related procedures were complied with The Association for Research in Vision and Opthamology (ARVO) Statement for the use of animals in ophthalmic and vision research. The study was approved by Fırat University Animal Care and Use Committee. *P. aeruginosa* American Type Culture Collection 27853 was used to generate endophthalmitis. Thirty-six healthy New-Zealand White rabbits weighing 2500-3000 g were divided into 6 equal groups. The right eyes of rabbits in Group 1 to Group 5 received 2 × 10^4^ colony-forming unit (CFU)/0.1 ml intravitreal injections of *P. aeruginosa* suspension. Group 6 was used as control and received intravitreal 0.1 ml sterile physiological saline. Rabbits in Group 2 to Group 5 were treated with intravitreal antibiotics (Group 2 = 0.5 mg/0.1 ml cefepime, Group 3 = 1 mg/0.1 ml cefepime, Group 4 = 2 mg/0.1 ml cefepime, Group 5 = 1 mg/0.1 ml ceftazidime). No treatment was given to rabbits in Group 1. The antibiotics were injected into the vitreous cavity by using a 30-gauge needle attached to a tuberculin syringe. The eyes of rabbits in each group were examined clinically on 1^st^, 3^rd^, and 6^th^ day of the experiment. Severity of endophthalmitis was graded clinically by using a scoring system that previously reported by Pleyer *et al*.\[[@ref4]\] At 6^th^ day, 0.1 ml vitreous humor aspirates were obtained and plated for quantification on blood agar and the results were expressed as CFU/ml. Subsequently, the eyeballs were enucleated and the histopathological evaluation was performed. Histopathological findings were scored with a scale that previously described by Meredith and associates.\[[@ref5]\]

Statistical analysis was performed with the SPSS version 15 to determine the differences between the three treatment groups. The Wilcoxon test, Mann-Whitney U test, and Kruskal-Wallis test were used in the statistical analysis as indicated. *P* values smaller than 0.05 were considered statistically significant.

Results {#sec1-2}
=======

The mean and the standard deviation of clinical scores in 1^st^, 3^rd^ and 6^th^ day after inoculation in groups are presented in [Table 1](#T1){ref-type="table"}. In 3^rd^ day, there was no clinical difference between Group 1 and Group 2, but in 6^th^ day a marked decline was noted in the clinical inflammatory findings in all treatment groups when compared with Group 1.
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Mean and standard deviation of CFU/ml values in groups are given in [Table 1](#T1){ref-type="table"}. Group 1 had significantly more CFU/ml when compared with the treatment groups. There was no statistically significant differences in mean CFU/ml values between treatment groups (Group 2 to Group 5), but the mean CFU/ml values of eyes in these groups and in Group 1 were significantly higher when compared with uninfected controls.

The mean and the standard deviation of the histopathological scores in groups are presented in [Table 1](#T1){ref-type="table"}. Histopathological examination in Group 1 and in Group 2 denoted severe inflammation in the vitreous cavity and total destruction of the retinal architecture \[Figs. [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}\]. Histopathological findings were similar in Group 3, 4, and 5 \[[Fig. 4](#F4){ref-type="fig"}\].

![The view of normal retinal architecture in Group 6 (control group) (H and E, ×100)](IJO-61-525-g002){#F1}

![Severe exudation and abscess formation in the vitreous cavity, dense inflammation in retina and total destruction of the retinal architecture and total retinal detachment is seen in one eye in Group 1 (untreated infected group) (H and E, ×100)](IJO-61-525-g003){#F2}

![Abscess formation in the vitreous cavity, dense inflammation in retina and diffuse retinal necrosis and retinal detachment is seen in an eye in Group 2 (0.5 mg/ml cefepime) (H and E, ×100)](IJO-61-525-g004){#F3}

![Preservation of retinal architecture, minimal neutrophil infiltration, and minimal exudation in vitreous cavity is seen in one eye in Group 3 (1 mg/ml cefepime) (H and E, ×100)](IJO-61-525-g005){#F4}

Discussion {#sec1-3}
==========

Available data suggest that the cefepime may have advantages over ceftazidime owing to a broader spectrum of activity and reduced potential for development of bacterial resistance.\[[@ref6]\] Compared with ceftazidime, cefepime has enhanced activity *in vitro* against Gram positive bacteria, including meticillin-sensitive *Staphylococcus aureus* and *Streptococcus pneumoniae*.\[[@ref7]\] Cefepime has better activity against gram-negative bacteria that produce extended spectrum β-lactamase and has broadened antipseudomonal activity than the ceftazidime.\[[@ref6]\] Jay and Shockley delineated the dose-and time-dependent retinal toxicity of cefepime using electroretinography in pigmented rabbit eyes. Electroretinographic patterns at 1^st^ and 2^nd^ weeks indicated a toxic response to 20 mg of cefepime. B-waves were normal at 1^st^ and 2^nd^ weeks for rabbits receiving doses of 0.5 mg to 10 mg. Pharmacokinetic analysis after single intra-vitreal injection of 1 mg of cefepime disclosed the following vitreous fluid levels (μg/ml): 645 at O h, 431 at 8 h, 235 at 24 h, and 23 at 72 h. Peak aqueous humor levels (56 μg/ml) were observed at 8 h after injection.\[[@ref8]\]

The evaluation of clinical results in this study demonstrated that in 3^rd^ day after inoculation there was no difference between Group 1 and Group 2, but in 6^th^ day, a marked decline was noted in the clinical inflammatory findings in all treatment groups when compared with Group 1. These findings suggest that 0.5 mg/0.1 ml intravitreal cefepime was not sufficient to clinically control the *P. aeruginosa* endophthalmitis. Bacterial culture results showed us there was no statistically significant difference in mean CFUs/ml values between the treatment groups, but in Group 4 (2 mg/0.1 ml cefepime) the mean CFU/ml value was the least. Histopathological examination in Group 1 and in Group 2 denoted severe exudation and abscess formation in the vitreous cavity, dense inflammation in the retina and total destruction of the retinal architecture and partial or total retinal detachment. These results imply that 0.5 mg/0.1 ml cefepime was not satisfactory for preserving of normal retinal architecture.

In summary, intravitreal cefepime may be an alternative drug in the treatment of *P. aeruginosa* endophthalmitis. Clinical and the histopathological results in our study indicate that 0.5 mg/ml cefepime is not satisfactory in the treatment of *P. aeruginosa* endophthalmitis. Intra-vitreal 1 mg/0.1 ml cefepime is as effective as intra-vitreal 1 mg/0.1 ml ceftazidime. Although increasing the intra-vitreal cefepime dose beyond 1 mg/0.1 ml provides additional benefits, this is not statistically significant. Hypothetically, taking into consideration the broad spectrum and lower resistance rates of cefepime, it may be an alternative drug in the treatment of endophthalmitis caused by other bacteria. Further, *in vivo* and *in vitro* studies need to be carried out to more accurately assess this subject.
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